Publicacions en què col·labora amb Marta Santisteban Eslava (15)

2024

  1. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

    Clinical and Translational Oncology

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

2020

  1. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 6, pp. 906-912

  2. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 4, pp. 523-530

2018

  1. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

    Breast Journal, Vol. 24, Núm. 4, pp. 473-479

  2. Erratum: Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial (Brachytherapy (2018) 17(5) (734–741), (S1538472118300898) (10.1016/j.brachy.2018.04.007))

    Brachytherapy

  3. Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial

    Brachytherapy, Vol. 17, Núm. 5, pp. 734-741

2016

  1. Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation

    Brachytherapy, Vol. 15, Núm. 4, pp. 485-494

2015

  1. 37th Annual San Antonio Breast Cancer Symposium. Summary of the most important translational and clinical contributions

    Revista de Senologia y Patologia Mamaria

  2. Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors

    Minerva Chirurgica

2013

  1. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: A retrospective cohort study

    Journal of Neuro-Oncology

2010

  1. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

    Cancer Chemotherapy and Pharmacology, Vol. 65, Núm. 3, pp. 457-465

2006

  1. Docetaxel administered during pregnancy for inflammatory breast carcinoma

    Clinical Breast Cancer, Vol. 6, Núm. 6, pp. 533-534